Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

PURPOSE: Patients with advanced pancreatic adenocarcinoma have a poor prognosis and limited second-line treatment options. Evidence suggests a role for the Janus kinase (JAK)/signal transducer and activator of transcription pathway in the pathogenesis and clinical course of pancreatic cancer. PATIEN...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Hurwitz, Herbert I., Uppal, Nikhil, Wagner, Stephanie A., Bendell, Johanna C., Beck, J. Thaddeus, Wade, Seaborn M., Nemunaitis, John J., Stella, Philip J., Pipas, J. Marc, Wainberg, Zev A., Manges, Robert, Garrett, William M., Hunter, Deborah S., Clark, Jason, Leopold, Lance, Sandor, Victor, Levy, Richard S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2015
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089161/
https://ncbi.nlm.nih.gov/pubmed/26351344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.4578
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge